INTERVIEW: Evotec CEO On Tears, Transparency And Trying Again
Executive Summary
Werner Lanthaler talks to Jo Shorthouse about partnering with big pharma on drug discovery, remaining authentic, and creating the 'half pregnant' company that Evotec is today.
You may also be interested in...
Further Sanofi Deals Move Evotec On From Development Setbacks
Evotec has signed two more R&D deals with French major Sanofi that it hopes will help it move on from previous R&D disappointments.
Roche/Evotec's Alzheimer's candidate fails
Roche and Evotec look set to drop their MAO-B inhibitor sembragiline from development for Alzheimer's following disappointing Phase IIb data. The product appears to be a late swansong for this mechanism of action in Alzheimer's: previous similar candidates failed around 15 years ago, and the only other investigational MAO-B inhibitors still in the running are at the preclinical stage.
Evotec sues Andromeda after DiaPep277 deception
Germany's Evotec has taken legal steps against Israel's Andromeda Biotech in an effort to recoup its losses following Andromeda's falsification of trial results for diabetes drug DiaPep277. Evotec's stock took a dive when the deception came to light earlier in September and has yet to recover.